USA flag logo/image

An Official Website of the United States Government

Optimization of a Multivalent Tuberculosis Vaccine

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85342
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
AI075830
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
EPIVAX, INC.
146 CLIFFORD STREET PROVIDENCE, RI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Optimization of a Multivalent Tuberculosis Vaccine
Agency: HHS
Contract: 1R43AI075830-01
Award Amount: $590,912.00
 

Abstract:

DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit immunity to prevent reactivation of latent TB. This epit ope-driven, DNA-prime, protein-boost TB vaccine has been in development since 1997, when our immunoinformatics tools were first applied to identify T cell epitopes from TB proteins. In progress made during the three years of NIH and Sequella/Aeras TB Found ation support, we completed mapping of three sets of TB epitopes including novel epitopes predicted directly from the TB CDC1551 genome. In the next phase of the research program, building on our own experiences and our collaborations, we seek to develop t he optimal vaccination strategy, using HLA transgenic mice as the model for in vivo study. Before the start of the performance period, we will make the final epitope selections. In the course of the SBIR award period, selected epitopes will be formulated a s DNA and peptide/protein vaccines. By means of a prime-boost vaccination strategy, we will optimize key vaccination parameters (administration route, antigen targeting, adjuvant) to induce the greatest immunogenicity as assessed by cytokine production of stimulated immune cells. Next, we will determine the protective efficacy of the optimized TB vaccine against the standard bacilli Calmette-Gu rin (BCG) vaccine and as a boost in HLA transgenic mice pre-vaccinated with BCG. Successful completion of this wor k will set the stage for Phase II development that will partner the vaccine with improved recombinant BCG vaccines and assess efficacy in additional strains of HLA transgenic mice.

Principal Investigator:

Anne S. Degroot
4012722123
ANNIED@EPIVAX.COM

Business Contact:

Julie M. Mcmurry
grants@epivax.com
Small Business Information at Submission:

EPIVAX, INC.
146 CLIFFORD STREET PROVIDENCE, RI 02903

EIN/Tax ID: 050499380
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No